Jennifer Bath, CEO of MindWalk Holdings Corp., stated on the Q1 FY2027 earnings call that the company is progressing towards its goal of becoming the leading bio-native AI drug discovery and development company. MindWalk launched its proprietary data platform, ReefIQ, in June and is now focused on enterprise adoption, having engaged with several large pharmaceutical companies regarding potential enterprise deployment of ReefIQ. The company's clients include 19 of the top 20 global pharmaceutical companies. Additionally, MindWalk partnered with AMD and Vultr to validate the production deployment of OpenFold3 on AMD Instinct MI325X GPUs, with initial results to be released this week. The company also announced a binding commitment, the specifics of which were not detailed in the minutes.